NEW YORK, Nov. 11 (GenomeWeb News) - Shares in Lynx Therapeutics were up 11.6 percent at $2.99 in mid-afternoon Nasdaq trading, two days before the embattled company is to report its third-quarter earnings.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.